EVARREST was associated with potential perioperative cost savings in indicated patients across a broad range of surgical specialties in clinical trials, including^A:

• $582 in soft tissue & liver procedures^6-11
• $3,757 in soft tissue & liver coagulopathic sub-set procedures^B,C5-11
• $3,804 in cardiovascular procedures in anti-coagulated patients^D6,12

_{A. Perioperative costs included operating time, retreatment, and transfusions. 
B. Net cost savings determined by comparing EVARREST to SoC based on product acquisition cost, surgery time, transfusion requirements, and retreatment effect. SoC varied across trials cited.
C. Patients potentially coagulopathic, defined by a coagulation parameter outside of normal reference range.
D. Cardiovascular surgery efficacy claims refer to head-to-head study of EVARREST and TachoSil® Fibrin Sealant Patch}
 

EVARREST demonstrated superior hemostatic efficacy in 4 randomized controlled clinical trials across a spectrum of challenging bleeding situations and surgical procedures.^1-4

• Trial 1: Soft Tissue hemorrhage (ITT population=90). 
• Trial 2: Normal and Abnormal liver resection hemorrhage (ITT population=84). 
• Trial 3: Anatomic and nonanatomic liver resection hemorrhage (ITT population=102). 
• Trial 4: Aortic reconstruction (ITT population=156).

_{EVARREST demonstrated hemostatic superiority across 4 clinical trials. Trial 1: Soft Tissue hemorrhage: Per protocol efficacy measured at n=87, 100% vs 53.3% for Surgicel Δ 46.7% P<0.0001; (ITT population=90). Trial 2: Normal and Abnormal liver resection hemorrhage: Per protocol efficacy measured at n=77, 94.3% vs 28.6% for conventional adjunctive methods Δ 65.7% P<0.001; (ITT population=84). Trial 3: Anatomic and nonanatomic liver resection hemorrhage: Per protocol efficacy measured at n=93, 97.9% vs 44.4% for conventional adjunctive methods Δ 53.5% P<.0001; (ITT population=102). Trial 4: Aortic reconstruction: Per protocol efficacy measured at n=141, 78.8% vs 46.7% for Tachosil Δ 32.1% P<0.0001; (ITT population=156).}

EVARREST was clinically proven to achieve hemostasis more reliably than TachoSil Patch in a multicenter, randomized study in aortic reconstruction surgery, achieving hemostasis in 3 minutes in 78.8% of cases vs 46.7% (per protocol; ITT population=141).¹³

After appropriate application and manual compression for 3 minutes, blood seeps into the EVARREST patch rather than pooling beneath it. Blood activates fibrinogen and thrombin to form a clot. Hemostasis is achieved when the clot integrates with the patch and adheres to the tissue surface.⁵